Abstract
N early 6 of 10 general practitioners in the UK acknowledge that they do not prescribe their patients the best treatment available from the National Health Service (NHS), according to an ABPI survey.* This may, in part, reflect a shift in attitude among NHS commissioners, where new drugs are increasingly viewed as causes of budgetary difficulty rather than welcomed as innovative treatments for ill health. All this adds up to a growing demand for new technologies to justify their costs before adoption by the NHS.
This is a preview of subscription content, log in via an institution to check access.
Additional information
* The results of the survey commissioned by the Association of the British Pharmaceutical Industry (ABPI) were released in February this year.
Rights and permissions
About this article
Cite this article
Wright, T. Managing new drug entry into the UK NHS. Pharmacoecon. Outcomes News 216, 3–4 (1999). https://doi.org/10.1007/BF03280085
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03280085